BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37705321)

  • 21. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents.
    Hoch M; Huth F; Sato M; Sengupta T; Quinlan M; Dodd S; Kapoor S; Hourcade-Potelleret F
    Clin Transl Sci; 2022 Jul; 15(7):1698-1712. PubMed ID: 35616006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C; Fan B; Ke A; Le K; Yang H
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
    Gaudy A; Atsriku C; Ye Y; MacGorman K; Liu L; Xue Y; Surapaneni S; Palmisano M
    Eur J Clin Pharmacol; 2021 Feb; 77(2):223-231. PubMed ID: 32965548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants.
    Patel M; Chen J; McGrory S; O'Gorman M; Nepal S; Ginman K; Pithavala YK
    Invest New Drugs; 2020 Feb; 38(1):131-139. PubMed ID: 31728714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, Tolerability, and Pharmacokinetics of Valemetostat Tablets and the Effect of Food on Valemetostat Pharmacokinetics in Healthy Subjects: Two Phase 1 Studies.
    Tachibana M; Matsuki S; Toyama K; Maekawa Y; Fukae M; Shimizu T; Tsutsumi J; Shinohara S; Ishizuka H
    Clin Pharmacol Drug Dev; 2024 Jan; 13(1):77-86. PubMed ID: 37565616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults.
    Cox DS; Van Eyck L; Pawlak S; Beckerman B; Linn C; Ginman K; Thay Cha Y; LaBadie RR; Shi H; Damle B
    Br J Clin Pharmacol; 2023 Sep; 89(9):2867-2876. PubMed ID: 37184075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
    Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
    Malhi V; Colburn D; Williams SJ; Hop CE; Dresser MJ; Chandra P; Graham RA
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):41-9. PubMed ID: 27154174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers.
    Hu C; Zhang Y; Pei T; Liu P; Zhang L
    Cancer Chemother Pharmacol; 2023 Jun; 91(6):523-529. PubMed ID: 37166499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant.
    Landry I; Aluri J; Nakai K; Hall N; Miyajima Y; Ueno T; Dayal S; Filippov G; Lalovic B; Moline M; Reyderman L
    Clin Pharmacol Drug Dev; 2021 Jun; 10(6):681-690. PubMed ID: 33455055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects.
    Barbour AM; Punwani N; Epstein N; Landman R; Cimino E; Yuska B; Wang P; He K; Chen X; Yeleswaram S
    J Clin Pharmacol; 2019 Dec; 59(12):1641-1647. PubMed ID: 31282592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug-drug interaction study.
    Hu X; Hsieh CY; Zhang Y; Liu W; Xu S; Cai SX; Liu L; Zhang M; Shi H; Zhang H; Liu P; Li X; Xu P
    Br J Clin Pharmacol; 2023 Jun; 89(6):1767-1779. PubMed ID: 36458825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase 1, Open-Label Study to Evaluate the Effect of Food and Concomitant Itraconazole Administration on the Pharmacokinetics of AMG 986 in Healthy Subjects.
    Trivedi A; Mather O; Vega S; Hutton S; Hellawell J; Lee E
    Clin Pharmacol Drug Dev; 2022 Jul; 11(7):849-856. PubMed ID: 35247290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.
    Riddell K; Patel A; Collins G; Zhou Y; Schramek D; Kremer BE; Ferron-Brady G
    J Clin Pharmacol; 2021 Jan; 61(1):125-137. PubMed ID: 32820548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of CYP3A4 induction and inhibition on the pharmacokinetics of SHR0302 in healthy subjects.
    Zhang Z; Gao X; Zhang P; Li Y; Fu M; Lin H; Feng S; Shen K; Yu G; Li X
    Br J Clin Pharmacol; 2023 Aug; 89(8):2561-2568. PubMed ID: 37005376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
    Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
    Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the Cytochrome P450 3A and P-glycoprotein Drug-Drug Interaction Potential of Futibatinib.
    Yamamiya I; Hunt A; Takenaka T; Sonnichsen D; Mina M; He Y; Benhadji KA; Gao L
    Clin Pharmacol Drug Dev; 2023 Oct; 12(10):966-978. PubMed ID: 37132707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy.
    Chen B; Zhou D; Wei H; Yotvat M; Zhou L; Cheung J; Sarvaria N; Lai R; Sharma S; Vishwanathan K; Ware J
    Br J Clin Pharmacol; 2022 Aug; 88(8):3716-3729. PubMed ID: 35165925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of drug-drug interactions of pemigatinib in healthy participants.
    Ji T; Rockich K; Epstein N; Overholt H; Wang P; Chen X; Punwani N; Yeleswaram S
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1887-1897. PubMed ID: 34282472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.